Send to

Choose Destination
Oncol Lett. 2018 Jul;16(1):1312-1320. doi: 10.3892/ol.2018.8780. Epub 2018 May 22.

Analysis of variants at LGALS3 single nucleotide polymorphism loci in skull base chordoma.

Tian K1,2,3,4, Wang L1,2,3,4, Wang K1,2,3,4, Ma J1,2,3,4, Li D1,2,3,4, Yang Y1,2,3,4, Jia G1,2,3,4, Wu Z1,2,3,4, Zhang L1,2,3,4, Zhang J1,2,3,4.

Author information

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China.
Center of Brain Tumor, China National Clinical Research Center for Neurological Diseases, Beijing 100050, P.R. China.
Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing 100050, P.R. China.
Beijing Key Laboratory of Brain Tumor, Beijing 100050, P.R. China.


Although LGALS3 has been widely studied, the genotypes of the LGALS3 single nucleotide polymorphism (SNP) loci in skull base chordoma (SBC) have been not well defined. The aim of the current study was to analyze two LGALS3 SNP genotypes in patients with SBC. A total of 48 patients with SBC who underwent surgical treatment in Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University (Beijing, China) and 66 healthy participants were included in the present study. A total of two SNPs (LGALS3+191 C>A and LGALS3 +292 A>C) were selected for sequencing analysis of amplified target fragments from DNA that was extracted from blood samples. The clinical features of the patients were recorded, follow-up was conducted and statistical analysis was performed with SPSS 20.0. There were no differences in age and sex between the patients and control group. In addition, there were no significant differences in the distribution of genotypes (P=0.662) and allelic frequencies (P=0.638) at LGALS3+191 C>A between the two groups. However, significant difference was observed in the allelic distributions at LGALS3 +292 A>C between them (P=0.016), and allele A was associated with the occurrence of SBC. The distribution of the genotypes at LGALS3 +292 A>C was not significantly different in the additive model (CC vs. AC vs. AA, P=0.083) but was significantly different in the dominant model (CC+AC vs. AA, P=0.043). In the Kaplan-Meier analysis, there were no significant differences in the overall survival and progression analysis between different genotypes at LGALS3 +191 C>A (P=0.168 and P=0.120) in patients with SBC. There was no significant difference in overall survival was observed between the genotypes at +292 A>C (P=0.595). However, the progression-free survival (PFS) time of the CC+AC genotype group was longer compared with the AA genotype group (P<0.001). In the univariate and multivariate analysis of tumor progression, PFS was shorter in the AA genotype group compared with the CC+AC genotype group (P<0.001). The allele A and AA genotype at LGALS3 +292 A>C were observed to be associated with a higher risk of SBC, and the AA genotype at +292 A>C was associated with a shorter PFS time.


chordoma; galectin-3; gene; skull base

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center